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Background: X-linked agammaglobulinemia (XLA) is a rare inherited disease characterized by recurrent bacterial
infections, a paucity or absence of peripheral lymphoid tissue, an absence of circulating B cells, and marked
depression of serum IgG, IgA, and IgM. Germline mutation of the BTK gene has been identified as a cause of XLA.
These mutations cause defects in early B cell development.
Case presentation: In this study, we report a variant form of XLA with partial B cell function that results from a
missense mutation (c.1117C > G) in exon 13 of the BTK gene. A genetic analysis of the family revealed an affected
male sibling with a c.1117C > G mutation. He was observed with low level of serum immunoglobulin and CD19+ B
cell and received the IVIG replacement therapy regularly in follow up. Four female carriers were found.
Conclusion: BTK mutation analysis is necessary in the diagnosis of XLA and may be used for subsequent genetic
counseling, carrier detection and prenatal diagnosis.
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X-linked agammaglobulinemia (XLA), also known as Bru-
ton agammaglobulinemia, is the major immunodeficiency
disease (PID) identified in childhood [1]. XLA is a primary
immunodeficiency disease caused by a severe block of B
cell development at the pre-B to immature B cell stage
that is induced by mutations of the human Bruton’s tyro-
sine kinase (BTK) gene [2]. The main clinical symptoms of
XLA include recurrent severe infections and dramatically
decreased B cell and immunoglobulin levels [3].
The BTK gene is located at Xq21.3-Xq22 and encom-
passes 37.5 kb that contain 19 exons. The BTK protein
that is encoded by the BTK gene has 5 different functional
domains; i.e., the PH, TH, SH3, SH2, and TK domains [4].
Any mutation that occurs in any site within one of these 5
domains can affect the activity of the tyrosine kinase and
thus influence the maturation of pre-B cells [5,6]. Here,
we reported a case of XLA that was induced by a BTK* Correspondence: yuhaiguo73@126.com
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unless otherwise stated.gene mutation and the results of examinations of the
genetic mutations in the patient’s family.
Case presentation
A 6-year-old boy was admitted to our hospital for recur-
rent intermittent fever for more than 2 years. This recur-
rent fever reached a peak temperature of 39°C and was
initially found in June of 2011. His temperature decreased
to within the normal range following after anti-infective
therapies. In the subsequent 2 years, the boy experienced 1
episode of septicemia (staphylococcus aureus), 3 episodes
of otitis media (etiology unknown), 2 episodes of pneumo-
nia (staphylococcus aureus and streptococcus pneumoniae)
and 4 episodes of bronchitis (etiology unknown). Anti-
infective therapies were administered for these episodes to
restore normal temperatures. This boy again exhibited
cough and fever one month prior to admission to our hos-
pital for further diagnosis and treatment. Upon admission,
X-ray revealed patchy high-density shadows that were
distributed along the lower left lobe of the lungs and mild
bilateral pulmonary emphysema. Sputum culture revealed
streptococcus pneumoniae that was sensitive to ceftriax-
one. The patient’s temperature returned to normal after aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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galy or lymphadenopathy was identified despite the
recurrent infections of the patient. A routine blood
examination was also performed, and the results were
as follows: WBC 11.77 × 10^9 /L, N 29.8%, L 60.1%, Hb
119 g/L, PLT 304 × 10^9/L, CRP 47 mg/L, and ESR
23 mm/H. Blood biochemistry examination revealed
the following: Alanine aminotransferase (ALT)5 U/L, As-
partate aminotransferase (AST )24 U/L, Lactate dehydro-
genase (LDH) 320 U/L, Creatine kinase (CK) 72 U/L,
Creatine kinase-MB CK-MB 23 U/L, Alpha-hydroxybuty-
rate dehydrogenase( HBDH )275 U/L, Total protein (TP )
57.3 g/L, Albumin 40.6 g/L, and Globulin 16.7 g/L.
The renal function and electrolyte levels of the pa-
tient were normal. The ferritin level was 287.4 ng/ml
(normal, 80–130 ng/ml). The immune parameters
were consistent with primary agammaglobulinemia:
IgG < 0.34 g/L (normal, 6–12 g/L), IgA <0.264 g/L
(normal, 0.7-3 g/L), IgM 0.179 g/L (normal, 0.5-3 g/L),
and the level of circulating CD19 + B-lymphocytes was
dramatically reduced to 0.2%, (normal 5-15%, absolute
count: 25 /mm3). XLA was diagnosed based on the com-
bination of profound hypogammaglobulinemia of all threeFigure 1 Identification of the BTK gene mutation. (A) The segment of
segment of exon 13 in the BTK in the hemizygous mutation proband. (C) T
(D) Heredity map of the family with the proband (III-1).immunoglobulin isotypes, the low CD19+ B-lymphocyte
count together and the male gender. The final diagnosis
was confirmed by molecular DNA analysis.
Genetic analysis
After informed consent had been obtained, genomic
DNA was extracted from peripheral blood samples for
molecular genetic analysis of the BTK gene. Sequencing
of the BTK coding regions revealed a point mutation,
c.1117C > G, that resulted in the amino acid substitution
L373V in the SH2 domain (Figure 1B). To our knowledge,
this is the first report of the mutation c.1117C >G at exon
13 in the literature.
After the proband diagnosis was confirmed, the pa-
tient’s 13 living family members were informed, and
consent was obtained from these family members for
purpose of genetic analysis. Genetic analysis of the family
members revealed an affected 1-year –old male cousin
with a c.1117C >G mutation (III-2). We observed sig-
nificant CD19+ B cell deficiency (1.0%,absolute count:
55/mm3) with very low serum IgG 3.05 g/L, IgA 0.02 g/L,
IgM 0.08 g/L. He did not present a severe infections with
the exception of mild upper respiratory infections. Fourexon 13 of BTK in the normal family members. (B) Mutation in the
he segment of exon13 of BTK in the heterozygous family members.
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mutation (II-1, II-3, II-7, and I-1) (Figure 1C). The other
members were normal and free of any genetic mutations
in BTK.
Analysis of the family pedigree
The analysis of the family pedigree of the proband
(Figure 1D) after completing all the findings of DNA
sequencing, clinical and other laboratory studies indi-
cated that the proband in the family had an inherited
X-linked recessive manner, as described in the literature
by other authors [7].
Prediction of functional consequence of the
c.1117C > G mutation
The novel missense mutation c.1117C >G was shown to
be conserved in different species (Table 1). Computational
predictive analysis was undertaken using two algorithms:
SIFT, PolyPhen. These were tested to determine their ac-
curacy in predicting whether missense variants would be
deleterious to function. c.1117C >G is predicted to be
deleterious with a score of 0.00(DAMAGING) for SIFT,
0.996 (PROBABLY DAMAGING) for PolyPhen. These ev-
idences documented that the novel mutation identified in
this study is disease-causing.
Discussion
X-linked agammaglobulinemia (XLA) is a primary im-
munodeficiency disease that is caused by mutations in
the Bruton’s tyrosine kinase (BTK) gene. Symptoms,
including recurrent severe bacterial infection, hypogam-
maglobulinemia, and a remarkable reduction or lack
of B cells in the peripheral blood, can be found in
most of the patients with XLA shortly after birth [8].
As an X-linked recessive disease, the incidence rate of
XLA is around 0.5/100,000 [9]. Bruton’s tyrosine kinase












Amino acid conservation is indicated by boldface type.identified by positional cloning [10]. The BTK protein is a
member of the non-receptor protein tyrosine kinases of
Tec; these proteins can catalyze the phosphorylation of
tyrosine residues on various proteins and play important
roles in the signaling pathway that controls the develop-
ment of B lymphocytes. Mutations in any domain of the
BTK can induce dysfunction of the BTK protein, block
the development of pre-B cells from naive B cells,
and decrease the lifespan of mature B lymphocytes.
The lack of B lymphocytes and plasmocytes in the periph-
eral blood can decrease the synthesis of different immuno-
globulins, decrease specific responses to various antigens,
and thus ultimately induce immunodeficiency [11].
The BTK gene is localized at Xq21.3-Xq22 and encom-
passes 37.5 kb that contain 19 exons. The first exon of
the BTK gene is a non-coding region, and the other 18
exons code the BTK protein, which contains 659 amino
acids and has a relative molecular mass of 76000 Da
[12]. The most comprehensive database for BTK gene
variations is the BTKbase, Version 8.53 last updated 17
June, 2013 contains 1254 public entries. To date, 787 mu-
tations of the BTK gene that are associated with XLA have
been found in the Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BTK). Most
of these mutations are missense mutations, followed by
nonsense mutations, splice site mutations, insertions, and
deletions. Missense mutations primarily occur in the first
two bases of a triplet codon. Studies have reported that
mutations in the BTK gene can occur in the exons, in-
trons, and promoters [13,14]. In the present study, we
provide the first report of a novel missense mutation,
c.1117C >G, that was found in exon 13 and resulted in a
leucine to valine amino acid substitution (L373V) in the
encoded protein. The result of analyses with 2 online soft-
wares (PolyPhen-2 and SIFT) suggested that this mutation
affected the structure and function of the protein. Sequen-
cing analysis of exon 13 within the family pedigree revealedf BTK
AA Alignment
373 H Q H N S A G L I S R L K Y P V S Q Q N K N A
373 H Q H N S A G L I S R V K Y P V S Q Q N K N A
373 H Q H N S A G L I S R L K Y P V S Q Q N K N A
373 H Q H N S A G L I S R L K Y P V S Q Q N K N A
373 H Q H N S A G L I S R L K Y P V S K Q N K N A
371 H Q H N S A G L I S R L K Y P V S R H Q K S A
356 H Q H N A A G M V S R L K Y I V T T R M R
352 H Q H N A A G L V S R L K Y I V S N R A Q N A
373 X X X X X X X L I S R L K Y P V S Q Q N K N A
364 H Q H N A A G L I S R L K Y P V C S L R K T A
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the c.1117C > G mutation and that 4 female members
were c.1117C > G carriers.
This BTK genetic study is the most useful in atypical
XLA patient,whose serum IgG concentration are above
the diagnostic threshold and whose resulting clinical
manifestation are subtle. The treatment of XLA in-
cludes prophylactic therapy with IVIG and appropri-
ate antibiotics for acute and chronic infections. Earlier
reports suggest that high dose IVIG replacement therapy
(>400 mg/kg every 3 weeks) is more effective than low-
dose (<200 mg/kg) in patients with XLA [15]. In our
patient, gammaglobulin replacement therapy (IVIG,
400–600 mg/kg) was administered following the diagno-
sis. This therapy consisted of infusions of gammaglobulin
once every month for the first 3 months followed by sub-
sequent infusions once every 2–3 months. The concentra-
tion of serum IgG was 7.6 g/L in the follow up after the
first administration. The serum IgG levels were also moni-
tored and maintained above 5 g/L. No episodes of respira-
tory tract infection or fever were found during a 1-year
follow up. Gammaglobulin replacement therapy is non-
curative for the patients with XLA. Work from laboratories
demonstrates the feasibility of using gene-corrected HSCs
to complement the immune defects of BTK-deficiency in
mice [16]. We propose the clinical program of stem
cell based therapy for XLA should be started in the
very near future.Conclusions
These findings suggest that genetic analysis of the BTK
gene and evaluation of the immune function of sus-
pected patients could increase the diagnosis rate and
help clinicians to perform IVIG replacement therapy in
a timely manner, which might significantly decrease
the incidence of complications and the mortality rate.
Genetic analysis of the BTK gene might also aid the
identification of other patients and carriers in the pa-
tient’s family and might be used for subsequent genetic
counseling.Consent
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